Parkinson’s disease (PD) is a progressive neurological disorder characterized by motor and non-motor symptoms, primarily due to the degeneration of dopamine-producing neurons in the brain. As this condition affects millions worldwide, the Parkinson’s disease market is evolving rapidly, driven by new therapies, clinical trials, and key industry players. This article highlights the significant stakeholders in the Parkinson’s disease market, based on insights from DelveInsight's comprehensive report on the subject.
Request for Sample Report @ Parkinson’s Disease Market
Overview of the Parkinson’s Disease Market
Parkinson’s disease affects movement and coordination, leading to tremors, rigidity, bradykinesia, and postural instability. Non-motor symptoms include depression, anxiety, sleep disturbances, and cognitive impairments. Although there is no cure, current treatments aim to manage symptoms and improve quality of life through medications like levodopa and dopamine agonists, as well as therapies such as deep brain stimulation.
The Parkinson’s disease market is poised for substantial growth due to ongoing advancements in research, innovative treatments, and increased awareness. DelveInsight’s report highlights the expected market growth, trends, and key players shaping the future of Parkinson’s disease treatment.
Key Companies and Their Contributions
- Cerevel Therapeutics
- Therapies: Cerevel Therapeutics is developing innovative therapies for Parkinson’s disease, including Tavapadon. Their approach focuses on novel dopamine receptor agonists designed to offer improved efficacy and safety profiles.
- Pfizer
- Therapies: Pfizer, in collaboration with Cerevel Therapeutics, is working on Tavapadon. Their commitment to Parkinson’s disease research reflects their broader strategy of addressing neurodegenerative disorders through advanced therapeutics.
- Pharma Two B
- Therapies: Pharma Two B is advancing P2B001, a promising combination therapy for Parkinson’s disease. This therapy aims to enhance patient outcomes through a dual mechanism of action.
- AbbVie
- Therapies: AbbVie’s ABBV-951 (foscarbidopa/foslevodopa) is a significant development in the Parkinson’s disease market, designed to improve the delivery and effectiveness of levodopa therapy.
- Biogen
- Therapies: Biogen, in partnership with Denali Therapeutics, is working on BIIB122/DNL151, a potential disease-modifying therapy that targets alpha-synuclein, a protein implicated in Parkinson’s disease pathology.
- Denali Therapeutics
- Therapies: Denali Therapeutics’ collaboration with Biogen focuses on BIIB122/DNL151, reflecting their innovative approach to tackling Parkinson’s disease through novel mechanisms.
- Annovis Bio
- Therapies: Annovis Bio is developing Buntanetap, a compound targeting neuroinflammation and neurodegeneration, offering a potential new avenue for Parkinson’s disease treatment.
- Amneal Pharmaceuticals
- Therapies: Amneal Pharmaceuticals is advancing IPX203, an extended-release formulation of carbidopa-levodopa, aiming to enhance therapeutic efficacy and patient convenience.
- BioVie
- Therapies: BioVie is focusing on NE3107, a novel drug that targets neuroinflammation, offering new hope for improving Parkinson’s disease management.
- Cerevance
- Therapies: Cerevance’s CVN424 is a selective serotonin-norepinephrine reuptake inhibitor (SSNRI) in development, targeting motor and non-motor symptoms of Parkinson’s disease.
- Clene Nanomedicine
- Therapies: Clene Nanomedicine is advancing CNM-Au8, a nanomedicine that aims to improve cellular energy production and reduce oxidative stress in Parkinson’s disease.
- Intra-Cellular Therapies
- Therapies: Intra-Cellular Therapies is developing ITI-214 (lenrispodun), a selective phosphodiesterase-1 (PDE1) inhibitor that could offer new therapeutic options for Parkinson’s disease.
- Hoffmann-La Roche
- Therapies: Hoffmann-La Roche, in partnership with Prothena Corporation, is working on Prasinezumab (RO7046015/RG7935/PRX002), an antibody targeting alpha-synuclein aggregates to potentially modify disease progression.
- Prothena Corporation
- Therapies: Prothena’s collaboration with Hoffmann-La Roche on Prasinezumab highlights their commitment to developing disease-modifying therapies for Parkinson’s disease.
Market Dynamics and Trends
According to DelveInsight, the Parkinson’s disease market is expected to grow significantly by 2032. The market, valued at approximately USD 3.2 billion in 2022, is driven by several factors:
- Advancements in Therapies: The introduction of new drugs and therapies, including those in the late stages of development, is expected to enhance treatment options and market growth.
- Rising Patient Pool: Increasing prevalence of Parkinson’s disease due to an aging population contributes to the growing demand for effective treatments.
- Innovative Research: Ongoing clinical trials and research efforts are likely to yield new therapies, addressing unmet needs and expanding treatment possibilities.
Epidemiology and Patient Population
DelveInsight’s report provides a detailed analysis of the Parkinson’s disease epidemiology across seven major markets (7MM) – the United States, EU5 countries, and Japan. Key epidemiological insights include:
- Prevalence and Incidence: Trends in diagnosed prevalence and incidence rates help stakeholders understand the scope of the disease and plan for market needs.
- Demographic Insights: Gender-specific, age-specific, and stage-specific epidemiological data provide a comprehensive view of the patient population, aiding in targeted treatment strategies.
Request for Sample Report @ Parkinson’s Disease Market
Pipeline Development and Future Outlook
The Parkinson’s disease pipeline includes several promising therapies currently in Phase II and III trials. Key developments include:
- Tavapadon by Cerevel Therapeutics and Pfizer
- P2B001 by Pharma Two B
- ABBV-951 by AbbVie
- BIIB122/DNL151 by Biogen and Denali Therapeutics
These therapies represent a diverse range of approaches, from novel receptor agonists to disease-modifying agents, indicating a dynamic and evolving treatment landscape.
Conclusion
The Parkinson’s disease market is rapidly advancing, driven by significant contributions from leading pharmaceutical companies and innovative therapeutic developments. Key stakeholders, including Cerevel Therapeutics, Pfizer, AbbVie, and others, are at the forefront of this transformation, offering new hope for managing and potentially modifying the course of Parkinson’s disease. With ongoing research, clinical trials, and a growing understanding of the disease, the market is set to experience continued growth and innovation in the coming years.
For more detailed insights and analysis on the Parkinson’s disease market, including epidemiology, therapy assessment, and market forecasts, DelveInsight’s comprehensive report offers valuable information for stakeholders and industry participants.
Trending Reports:
Adrenal Insufficiency Market | Antibody Mediated Rejection Market | Antibody-mediated Rejection Market | Bone And Joint Infection Market | Cholangiocarcinoma Market | Cutaneous Lupus Erythematosus Market | Human Papillomavirus Positive Cancer Market | Italy Healthcare Outlook Report | Postmenopausal Vaginal Atrophy Market | Severe Hypertriglyceridemia Market | Abscess Market | Acute Ischemic Stroke Ais Market | Adrenoleukodystrophy Market | Cutaneous T-cell Lymphoma Market | Diffuse Cutaneous Systemic Sclerosis Market | Lhon Market | Uncomplicated Urinary Tract Infections Market | Ataxia Telangiectasia Market | Atypical Hemolytic Uremic Syndrome Ahus Market | Biliary Atresia Market | Biliary Tract Cancer Market | Chronic Inducible Urticaria Market | Chronic Refractory Gout Market | Diffuse Large B-cell Lymphoma Market | Myelofibrosis Market | Severe Hypoglycemia Market | Ankylosing Spondylitis Bekhterevs Disease Market | Cutaneous T Cell Lymphoma Market | Epidermolysis Bullosa Market | Idiopathic Membranous Nephropathy Market | Sjogren’s Syndrome Market | Balloon Catheters Market | Balloon Catheters Market Market | Central Retinal Venous Occulsion Market | Community-acquired Bacterial Pneumonia Market | Multiple Myeloma Market | Achromatopsia Market | Atopic Keratoconjunctivitis Akc Market | Bipolar Depression Market | Cardiac Insufficiency Market | Chronic Pain Associated With Painful Diabetic Neuropathy Market | Tim-3-next Generation Immunotherapy Market | Asmd Market | Calciphylaxis Market | Chronic Idiopathic Urticaria Market | Atypical Teratoid Rhabdoid Tumors Market | Cardiac Amyloidosis Market | Healthcare Pipeline Analysis | Hepatitis D Market | Interbody Cages Market | Endoscopy Fluid Management Systems Market | Helicobacter Pylori Infection Market | Lymphocytopenia Market
DelveInsight:
Top Market Research Companies | Healthcare Market Research | Market Research Firms | Market Research Companies | Conference Coverage | Competitive Intelligence Services
